INO and the Centre de Recherche Informatique de Montréal (CRIM) Join Forces to Accelerate the Adoption of Artificial Intelligence in Business

Training an artificial intelligence (AI)-based model to automate decision-making in an industrial context can be a complex exercise, especially for SMEs that are just starting to integrate AI into their operations. INO’s achievements in high-performance intelligent optical sensors for the collection of reliable and representative measurements, combined with the CRIM’s expertise in machine learning, and predictive data processing and generation will allow companies in multiple sectors (health, environment, transportation, aerospace, agrifood, information technologies, financial services, and manufacturing) to harness the power of artificial intelligence more easily.

Limitless potential for application

Among other applications, artificial intelligence models can carry out predictive maintenance and reduce interruptions on an assembly line, help a healthcare professional make a diagnosis, accelerate the discovery of medications, and—more broadly—achieve in a few days or minutes what would have taken years to accomplish with traditional means. Evolution is rapid and businesses will benefit from this partnership between INO and the CRIM to position themselves in the national market and on the international stage as large companies invest heavily in the development of AI-based technologies.

A first collaboration in the medical field

The recent pandemic and the supply difficulties that it caused have illustrated the importance of developing vaccines and various therapeutic and diagnostic tools quickly and on a large scale. The latter are often developed in bioreactors for which INO has developed an innovative intelligent optical monitoring technique to observe cell cultures and optimize the performance of manufacturing processes. Since it would be costly and difficult to build a database that would take all production contexts into account, the subject is ideal for the generation of synthetic data and analysis models based on artificial intelligence.

Artificial intelligence tools for improving drug production methods have a high potential for deployment in the Quebec and Canadian biomanufacturing markets.

“This collaboration will demonstrate the complementary roles of INO and the CRIM in accelerating the adoption of artificial intelligence in a growing number of companies operating in sectors of the future,” explained Alain Chandonnet, Chief Executive Officer of INO, and Françoys Labonté, Chief Executive Officer of the CRIM. “Our collaboration and the pooling of our expertise for the benefit of innovative companies should intensify,” they added.